Amesite Inc. (AMST) - 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended December 31, 2024. Amesite Inc. is a technology company developing AI-driven solutions, including a higher education platform and the NurseMagic™ healthcare app. The company is classified as a smaller reporting company and an emerging growth company. As of February 5, 2025, there were 3,994,107 shares of common stock issued and outstanding.
Key Financial Metrics
| Metric | Six Months Ended Dec 31, 2024 | Six Months Ended Dec 31, 2023 |
|---|---|---|
| Net Revenue | $24,010 | $104,776 |
| Net Loss | $(2,029,682) | $(1,796,304) |
| Loss Per Share (Basic & Diluted) | $(0.73) | $(0.71) |
| Cash and Cash Equivalents (End of Period) | $519,706 | $3,663,463 |
| Net Cash Used in Operating Activities | $(1,338,711) | $(1,577,832) |
| Total Assets | $2,136,202 | $3,314,177 |
| Stockholders' Equity | $1,247,465 | $2,515,712 |
Note: The filing does not provide explicit gross margin or operating margin percentages.
Material Changes vs. Prior Period
- Revenue Decline: Net revenue decreased by approximately 77% to $24,010 from $104,776 in the prior year period. Management attributes this to a strategic pivot away from large, cash-upfront deals that faced administrative barriers, toward a fee-per-course model for community colleges and AI tools for healthcare.
- Increased Net Loss: Net loss increased by approximately 13% to $2.03 million. This was driven by a significant increase in General and Administrative expenses (up to $1.44 million from $0.88 million), primarily due to Board stock compensation and professional fees.
- Expense Reductions: Technology and content development expenses decreased to $351,525 (from $664,658), and Sales and marketing expenses decreased to $292,924 (from $464,129), reflecting headcount reductions and refined marketing processes.
- Liquidity Position: Cash and cash equivalents dropped significantly from $2.07 million at June 30, 2024, to $519,706 at December 31, 2024, due to operating losses and capital expenditures.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: The company has raised substantial doubt about its ability to continue as a going concern. Management believes it may not have sufficient cash to maintain operations for the next twelve months without additional financing.
- Recent Financing: On January 8, 2025 (subsequent to the reporting period), the company closed a public offering of 1,201,667 shares at $3.00 per share, receiving net proceeds of approximately $3.08 million.
- Nasdaq Compliance: The company received a deficiency letter in November 2024 regarding failure to meet the $2.5 million stockholders' equity requirement. Following the January 2025 offering, Nasdaq determined the company had regained compliance as of January 23, 2025.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective due to material weaknesses, specifically regarding the review of journal entries, calculation of stock compensation, and classification of deferred revenue.
- Revenue Concentration: For the six months ended December 31, 2024, one customer represented 94% of total revenue.
Investor Verification Checklist
- Verify the sustainability of the new fee-per-course revenue model and the timeline for scaling beyond the single customer representing 94% of revenue.
- Confirm the utilization of the $3.08 million in proceeds from the January 2025 offering and whether it extends the runway beyond the current "substantial doubt" period.
- Monitor the remediation plan for material weaknesses in internal controls over financial reporting to ensure future reporting accuracy.
- Assess the company's ability to maintain Nasdaq listing compliance in future reporting periods given the history of equity deficiencies.
- Review the impact of the strategic pivot on long-term growth potential versus the short-term revenue decline.